Registered outcomes29

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

21 to 29 of 29

List	Outcome	Time frame	Description
Secondary	Incidence of AKI in both groups	1 year
Secondary	Incidence of SBP in both groups	6 months
Secondary	Incidence of SBP in both groups	1 year
Secondary	Incidence of severe hyponatremia in both groups	6 months
Secondary	Incidence of severe hyponatremia in both groups	1 year
Secondary	Incidence of refractory ascites in both groups	6 months
Secondary	Incidence of refractory ascites in both groups	1 year
Secondary	Maximum tolerated dose of carvedilol	1 year
Secondary	Tretament (carvedilol) related adverse events and their grades	1 year	Adverse Events are defined as incidence of Bradycardia,Hypotension,Breathlessness

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05057572/registered?page=2